Amatuximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Amatuximab
Accession Number
DB12845  (DB06122)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MORAb-009
Categories
UNII
6HP0354G04
CAS number
931402-35-6

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UMesothelinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Amatuximab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Amatuximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Amatuximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Amatuximab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Amatuximab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Amatuximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amatuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Amatuximab.
AnifrolumabThe risk or severity of adverse effects can be increased when Anifrolumab is combined with Amatuximab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911395
Wikipedia
Amatuximab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma1
1CompletedBasic ScienceCancer of the Ovary / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Mesothelioma1
1CompletedTreatmentCancer of the Ovary / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Mesothelioma1
1CompletedTreatmentMalignancies / Mesothelin-positive1
2Active Not RecruitingTreatmentMesothelioma, Malignant1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Membrane-anchored forms may play a role in cellular adhesion.Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
Gene Name
MSLN
Uniprot ID
Q13421
Uniprot Name
Mesothelin
Molecular Weight
68984.815 Da

Drug created on October 20, 2016 18:41 / Updated on November 02, 2018 07:30